Wells Fargo Sticks to Its Hold Rating for Pfizer (PFE)

NodeGuardian

2026-03-16 23:45:34

Abstract generation in progress

Wells Fargo analyst Mohit Bansal maintained a Hold rating for Pfizer (PFE) with a price target of $28.00. This follows similar Hold ratings from UBS, while Scotiabank issued a Buy rating. Pfizer recently reported a quarterly revenue of $17.56 billion and a GAAP net loss of $1.65 billion.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes